Document is current

Article History

Received: 4 October 2024

Accepted: 13 November 2024

First Online: 2 December 2024

Declarations

:

: JPL received research funding from Kazia Therapeutics and Lilly; and consulting honoraria from Minerva Biotechnologies. SMT reports consulting or advisory role for Novartis, Pfizer (SeaGen), Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, Gilead, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, Sumitovant Biopharma, Umoja Biopharma, Artios Pharma, Menarini/Stemline, Aadi Bio, Bayer, Incyte Corp, Jazz Pharmaceuticals, Natera, Tango Therapeutics, Systimmune, eFFECTOR, Hengrui USA, Cullinan Oncology, Circle Pharma, Arvinas, BioNTech, Johnson&Johnson/Ambrx, Launch Therapeutics, Zuellig Pharma, and Bicycle Therapeutics; institutional research support from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, Gilead, NanoString Technologies, Seattle Genetics, OncoPep, Daiichi Sankyo, and Menarini/Stemline; and travel support from Eli Lilly, Sanofi, Gilead, Jazz Pharmaceuticals, Pfizer, and Arvinas. NUL reports consulting honoraria from Puma, Seattle Genetics, Daiichi-Sankyo, AstraZeneca, Olema Pharmaceuticals, Janssen, Blueprint Medicines, Stemline/Menarini, Artera Inc., and Eisai; institutional research support from Genentech (and Zion Pharmaceutical as part of GNE), Pfizer, Merck, Seattle Genetics (now Pfizer), Olema Pharmaceuticals, and AstraZeneca; royalties from Up to date (book); and travel support from Olema Pharmaceuticals and AstraZeneca.

: The study was exempted from Institutional Review Board review because we utilized de-identified, previously collected, publicly available data. The study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.

: Not applicable.

: Not applicable.